2篇
您的检索式：作者名="Haibiao Lin"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Wavelength-Dependent Solar N_(2) Fixation into Ammonia and Nitrate in Pure Water显示文摘Solar-driven N_(2) fixation using a photocatalyst in water presents a promising alternative to the traditional Haber-Bosch process in terms of both energy efficiency and environmental concern.At present,the product of solar N_(2) fixation is either NH_(4)^(+)or NO_(3)^(-).Few reports described the simultaneous formation of ammonia(NH_(4)^(+))and nitrate(NO_(3)^(-))by a photocatalytic reaction and the related mechanism.In this work,we report a strategy to photocatalytically fix nitrogen through simultaneous reduction and oxidation to produce NH_(4)^(+)and NO_(3)^(-)byW18O49 nanowires in pure water.The underlying mechanism of wavelength-dependent N_(2) fixation in the presence of surface defects is proposed,with an emphasis on oxygen vacancies that not only facilitate the activation and dissociation of N_(2) but also improve light absorption and the separation of the photoexcited carriers.Both NH_(4)^(+)and NO_(3)^(-)can be produced in pure water under a simulated solar light and even till the wavelength reaching 730 nm.The maximum quantum efficiency reaches 9%at 365 nm.Theoretical calculation reveals that disproportionation reaction of the N_(2) molecule is more energetically favorable than either reduction or oxidation alone.It is worth noting that the molar fraction of NH_(4)^(+)in the total product(NH_(4)^(+)plus NO_(3)^(-))shows an inverted volcano shape from 365nm to 730 nm.The increased fraction of NO_(3)^(-)from 365 nm to around 427 nm results from the competition between the oxygen evolution reaction(OER)at W sites without oxygen vacancies and the N_(2) oxidation reaction(NOR)at oxygen vacancy sites,which is driven by the intrinsically delocalized photoexcited holes.From 427nm to 730 nm,NOR is energetically restricted due to its higher equilibrium potential than that of OER,accompanied by the localized photoexcited holes on oxygen vacancies.Full disproportionation of N_(2) is achieved within a range of wavelength from~427nm to~515 nm.This work presents a rational strategy to efficiently utilize the photoexcited carriers and optimize the photocatalyst for practical nitrogen fixation. | Wenju Ren Zongwei Mei Shisheng Zheng Shunning Li Yuanmin Zhu Jiaxin Zheng Yuan Lin Haibiao Chen Meng Gu Feng Pan | 2020 | Research2020，，1： | 1 |
| 2 | Anti-PD-L1 antibody enhances curative effect of cryoablation via antibody-dependent cell-mediated cytotoxicity mediating PD-L1^(high)CD11b^(+)cells elimination in hepatocellular carcinoma显示文摘Cryoablation(CRA)and microwave ablation(MWA)are two main local treatments for hepatocellular carcinoma(HCC).However,which one is more curative and suitable for combining with immunotherapy is still controversial.Herein,CRA induced higher tumoral PD-L1 expression and more T cells infiltration,but less PD-L1^(high)CD11b^(+)myeloid cells infiltration than MWA in HCC.Furthermore,CRA had better curative effect than MWA for anti-PD-L1 combination therapy in mouse models.Mechanistically,anti-PD-L1 antibody facilitated infiltration of CD8^(+)T cells by enhancing the secretion of CXCL9 from cDC1 cells after CRA therapy.On the other hand,anti-PD-L1 antibody promoted the infiltration of NK cells to eliminate PD-L1^(high)CD11b^(+)myeloid cells by antibody-dependent cell-mediated cytotoxicity(ADCC)effect after CRA therapy.Both aspects relieved the immunosuppressive microenvironment after CRA therapy.Notably,the wild-type PD-L1 Avelumab(Bavencio),compared to the mutant PD-L1 atezolizumab(Tecentriq),was better at inducing the ADCC effect to target PD-L1^(high)CD11b^(+)myeloid cells.Collectively,our study uncovered the novel insights that CRA showed superior curative effect than MWA in combining with anti-PD-L1 antibody by strengthening CTL/NK cell immune responses,which provided a strong rationale for combining CRA and PD-L1 blockade in the clinical treatment for HCC. | Jizhou Tan Ting Liu Wenzhe Fan Jialiang Wei Bowen Zhu Yafang Liu Lingwei Liu Xiaokai Zhang Songling Chen Haibiao Lin Yuanqing Zhang Jiaping Li | 2023 | Acta Pharmaceutica Sinica B2023，13，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员